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and Low Nrf2 Activation in Placenta Are Involved in
Preeclampsia
Yoshitsugu Chigusa, Keiji Tatsumi, Eiji Kondoh, Kohei Fujita,
Fumitomo Nishimura, Haruta Mogami, and Ikuo Konishi
Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto 606-
8507, Japan
Context: Serumconcentrationofoxidized low-density lipoprotein (oxLDL) is higher inwomenwith
preeclampsia than in normal pregnant woman. Lectin-like oxLDL receptor-1 (LOX-1) is one of the
scavenger receptors for oxLDL and is abundantly expressed in placenta. It is well known that oxLDL
activates nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of antioxidant and
cytoprotectivegenes suchashemeoxygenase-1 (HO-1),whichplayan important role inpreeclamp-
sia. However, it has yet to be elucidated whether LOX-1, along with Nrf2, participates in the
pathology of preeclampsia.
Objective: The objective of the study was to assess LOX-1 expression and Nrf2 activation in pre-
eclamptic placentas and to manifest their physiological roles in preeclampsia.
Methods: Expression and regulation of LOX-1, HO-1, and Nrf2 were evaluated by real-time quan-
titative RT-PCR and Western blotting. The functions of LOX-1 and Nrf2 were examined using an
anti-LOX-1 antibody and Nrf2 activator in JAR, a choriocarcinoma cell line, and placental explants.
Results: Both LOX-1 expression and Nrf2 activation were significantly decreased in preeclamptic
placentas compared with normal controls. A significant decrease in LOX-1 mRNA was found in
placental explant cultures under hypoxic conditions. Activation of Nrf2 up-regulated HO-1 in both
the JAR cells and placental explants. Furthermore, oxLDL increased HO-1 mRNA, whereas the
blockade of LOX-1 inhibited the increase of HO-1 mRNA in JAR cells.
Conclusion: Decreasing LOX-1 expression in preeclamptic placenta may contribute to high oxLDL
concentration, lowNrf2 activation, and lowHO-1 expression. These findings providenovel insights
into the crucial role of LOX-1 and Nrf2 in the pathogenesis of preeclampsia. (J Clin Endocrinol
Metab 97: E1862–E1870, 2012)
Preeclampsia is a pregnancy-specific multisystem disor-der, generally defined as new hypertension and sub-
stantial proteinuria at or after 20 wk of gestation (1, 2).
Despite the numerous clinical and basic studies, its etiol-
ogy and pathogenesis remain enigmatic, and only delivery
is regarded as a fundamental resolution. Therefore, pre-
eclampsia is still a leading cause of maternal and perinatal
mortalities and morbidities.
Maternal hyperlipidemia is one of the striking changes
to take place in lipidmetabolismduring even normal preg-
nancy (3). In women with preeclampsia, serum levels of
triglycerides, low-density lipoproteins (LDL) are higher
than those in normal pregnant women (4). In addition,
accumulating reports suggest that serum oxidized LDL
(oxLDL) are higher in preeclampsia (5, 6). OxLDL is es-
sential in the genesis and progression of atherosclerosis
(7). It can lead to endothelial dysfunction, a key feature of
preeclampsia (8), by binding to its scavenger receptors
including lectin-like oxidized low-density lipoprotein re-
ceptor-1 (LOX-1), CD36 and scavenger receptor A (SR-
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A). LOX-1 is a 52-kDa, type 2, single-transmembrane re-
ceptor cloned by Sawamura in 1997 (9) and present
primarily on endothelial cells and macrophages (10). Al-
though the basal expression of LOX-1 is very low, it can be
rapidly induced by various stimuli and several pathological
conditions, such as oxLDL, diabetes (11), and hyperlipid-
emia (12). Intriguingly, placenta is theorganwith thehighest
LOX-1expression,even inahealthystate (9), suggesting that
LOX-1 is crucial for maintaining pregnancy. However, the
underlying precise mechanism by which LOX-1 elicits its
effects in placenta and contributes to the maternal lipid me-
tabolism during pregnancy remains to be elucidated. In par-
ticular, the function of LOX-1 in placenta in context of pre-
eclampsia remains largely unknown.
Recently several studies have highlighted the impor-
tance of heme oxygenase-1 (HO-1) in pregnancy (13, 14).
HO-1 is an inducible enzyme that catalyzes the degrada-
tion of heme, yielding biliverdin, iron, and carbon mon-
oxide, a potent vasodilator (15). It has been implicated in
several physiological functions including the control of
vascular tone (16) and the regulation of the inflammation
(17) as well as contributing to the antioxidant capabilities
(18). It has been reported that the protein level of HO-1 is
decreased in preeclamptic placentas (17). Overexpression
ofHO-1 inendothelial cells results ina significantdecrease
in production of soluble fms-like tyrosine kinase 1 (sFlt-1)
and soluble endoglin (14). They are the most important
antiangiogenic circulating factors that are tightly associ-
ated with preeclampsia (19, 20). Furthermore, induction
of HO-1 attenuates hypertension in pregnancy hyperten-
sion model animals (13). However, the primordial cause
for the decrease of HO-1 in preeclamptic placenta has yet
to be elucidated. Nuclear factor erythroid 2-related factor
2 (Nrf2) is a key molecule that is activated in response to
oxidative stress and regulates antioxidant responsive ele-
ment mediated induction of cytoprotective genes (21). Al-
though Nrf2 is widely acknowledged as the predominant
upstream regulator of HO-1 and is activated by oxLDL
(22), the role ofNrf2 in placenta and howLOX-1 involves
in Nrf2 activation have not been clarified.
In the present study, we hypothesized that LOX-1 may
have an influence in preeclamptic placenta, leading toma-
ternal pathogenesis of preeclampsia through high serum
level oxLDL and endothelial dysfunction. We analyzed
the expression and regulation of LOX-1 and postulated
the relationship between LOX-1 andHO-1.We have also
focused on Nrf2 and investigated its relevance to LOX-1
in preeclamptic placenta. Based on these results, we will
discuss theputative role ofLOX-1andNrf-2on thepatho-
genesis of preeclampsia.
Materials and Methods
Patient characteristics and tissue collection
The clinical characteristics of patients enrolled in this study
are shown in Table 1. Preeclampsia was defined as maternal
systolic blood pressure of 140mmHg or greater and/or diastolic
blood pressure of 90 mmHg or greater in two consecutive mea-
surements, with an interval of 6 h, and proteinuria of 300 mg or
greater per 24 h after 20wk of gestation. Placental villous tissues
were collected from normal pregnant subjects (n 16) and pre-
eclamptic subjects (n  16), immediately after cesarean section
without labor at Kyoto University Hospital (Kyoto, Japan). The
tissueswere stored inRNAlater (Ambion,Austin, TX) after brief
rinsing in saline. The local ethics committee of the Graduate
School of Medicine, Kyoto University, approved the study pro-
tocol, and written informed consent was obtained from each
patient enrolled in this study.
Real-time quantitative RT-PCR
Total RNA extraction from placental tissues and cells was per-
formed using the RNeasyMini kit (QIAGEN, Germantown,MD)
according to the manufacturer’s instructions. RNA quality and
quantity was measured using a ND-1000 spectrophotometer
(Nanodrop, Wilmington, NC). Reverse transcriptsase of 1 g
RNAwas performed using the Rever Tra Ace (TOYOBO, Osaka,
Japan) according to themanufacturer’s instructions. The following
primers were designed using GeneFisher 2 software (Bielefeld Uni-
versity Bioinformatics Service, Bielefeld, Germany): LOX-1
(OLR1) (GenBankaccessionno.NM_002543.3),5-CACCACCA
GAATCTGAATCTCCAAG-3(forward),5-TTCAGCAACTTG
GCATCCAAAGAC-3 (reverse); CD36 (NM_001001548.2), 5-
TTGGAACAGAGGCTGACAACTTCAC-3 (forward), 5-ATG
GATCCCTATAGCCCCATAACAG-3 (reverse); SR-A (MSR1)
(NM_138716.2), 5-CTCATTGGAATAGTGGCAGCTCAA
C-3 (forward), 5-CTTCTCCATGTTGCTCATGTGTTCC-3
(reverse); sFlt-1 (U01134.1), 5-AGGGGAAGAAATCCTCCA-3
(forward), 5-CGAGCCTGAAAGTTAGCA-3 (reverse); leptin
TABLE 1. Clinical characteristics of the normal and preeclamptic (PE) patient groups
Normal (n  16) PE (n  16) P value
Patient’s age at delivery (yr) 35.6  5.2 (27–44) 33.8  4.0 (27–41) n.s.
Primipara (n) 7/16 11/16 —
Gestational age at delivery (wk) 38 37–38 34 32–37 0.01
Body mass index at delivery (kg/m2) 25.2  2.1 (21.2–29.1) 25.0  3.3 (21.0–33.4) n.s.
Systolic blood pressure at delivery (mm Hg) 106  6 (90–116) 168  16 (145–192) 0.0001
Diastolic blood pressure at delivery (mm Hg) 63  8 (52–80) 101  12 (80–124) 0.0001
Neonatal weight (g) 2969 2756.5–3189.5 1583.5 1290.5–2440 0.0001
Values are the mean  SD and (range) or median value with interquartile range. Dashes indicate the median value with interquartile range.
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(LEP) (NM_000230.2), 5-GTGCCCATCCAAAAAGTCCA-
AGAT G-3 (reverse); HO-1 (HMOX1) (NM_002133.2), 5-CC
AGGCAGAGAATGCTGAGTTCATG-3 (forward), 5-TGCA
GCTCTTCTGGGAAGTAGACAG-3 (reverse); glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (NM_002046.3), 5-GA
GTCAACGGATTTGGTCGTATTGG-3 (forward), 5-GCCA
TGGGTGGAATCATATTGGAAC-3 (reverse). Real-time quan-
titative RT-PCR was performed with SYBR premix Ex TaqII (Ta-
kara Bio, Otsu, Japan) using the LightCycler 480 real-time PCR
system (Roche Diagnostics, Mannheim, Germany) based on the
following run conditions: 95 C for 30 sec for initial denaturing
followed by 95 C for 5 sec and 60 C for 30 sec for 40 cycles. For
dissociation after PCR amplification, the protocol included slow
heating from 60 to 97 C to ensure amplification specificity. The
end result for gene expression was estimated using comparative
crossing point method for relative quantification. All data were
normalized and expressed relative to the GAPDH gene as an in-
ternal control. All samples were run in duplicates and quantitative
detection was averaged.
Cytosolic and nuclear extract preparation
Placental tissues were homogenized in radioimmunoprecipi-
tation assay buffer (50 mmol/liter Tris-HCl, pH 8.0; 150 mmol/
liter sodium chloride; 0.5% sodiumdeoxycholate; 0.1% sodium
dodecyl sulfate; 1.0% Nonidet P-40 substitute) supplemented
with cocktail protease inhibitor Complete Mini (Roche Diag-
nostics). The homogenized tissues were centrifuged at 10,000
g for 20 min 4 C, and the supernatant was saved as cytosolic
extract from placental tissues. The cells were washed with ice-
cold PBS, and cytosolic protein was extracted in the same man-
ner. Nuclear proteins from tissues and cells were prepared using
CelLytic NuCLEAR extraction kit (Sigma Aldrich, St. Louis,
MO) according to the manufacturer’s instructions. Protein con-
centrations were determined with a bicinchoninic assay protein
assay kit (Thermo Scientific, Rockford, IL).
Western blotting
Thirty micrograms of the cytosolic (for LOX-1 and HO-1
expression) or the nuclear (for Nrf2 expression) protein were
separated on 10% (LOX-1), 12% (HO-1), or 7.5% (Nrf2) so-
dium dodecyl sulfate-polyacrylamide gels, respectively. The sep-
arated proteinswere transferred onto nitrocellulosemembranes,
which were blocked with 5% fat-free milk overnight at 4 C. We
confirmed an equal amount of protein loading by Ponceau S
staining. The membranes were probed with rabbit polyclonal
antibodyagainstLOX-1 (1:250;ABGENT,SanDiego,CA), rab-
bit monoclonal antibody against HO-1 (1:2000; Abcam, Cam-
bridge, UK), or rabbit polyclonal antibody againstNrf2 (H-300)
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA). The blots
were subsequently incubated with appropriate secondary anti-
body (1:10,000; Santa Cruz Biotechnology). Rabbit polyclonal
antibody against -actin (1:5000; Abcam) and mouse monoclo-
nal antibody against TATA binding protein (1:3000; Abcam)
were used for cytosolic andnuclear loading control, respectively.
Signals were detected with ECL Plus Western blotting reagent
(GE Healthcare, Buckinghamshire, UK) and visualized by
ChemiDoc system (Bio-Rad Laboratories, Hercules, CA).
Immunohistochemistry
Immunohistochemical staining was carried out using the
streptavidin-biotin-peroxidase method. Formalin-fixed, paraf-
fin-embedded tissue sections were deparaffinized and antigen
retrieval was performed in Tris-EDTA buffer (pH 9.0) at 120 C
for 5 min. Endogenous peroxidase activity was blocked with
0.3%H2O2. The sectionswere incubatedwith rabbit polyclonal
antibody against LOX-1 (1:50; ABGENT) or normal rabbit IgG
overnight at 4 C, followed by incubation with biotinylated goat
antirabbit secondary antibody (Nichirei, Tokyo, Japan). Then
they were incubated with streptavidin-peroxidase complex so-
lution for 30 min. Signals were generated by treatment with
diaminobenzidine. Finally, the sections were counterstained
with hematoxylin and observed under the microscope.
Tissue and cell culture
Placental villous tissues were obtained from normal-term
pregnancies delivered by elective cesarean section in the absence
of labor. Small fragments of placental villi (10–20 mg) were
dissected from the placenta and washed in ice-cold PBS. Two
fragments were placed in six-well plates with 3 ml culture me-
dium (RPMI 1640 containing 10% fetal calf serum, 100 U/ml
penicillin, and 100 g/ml streptomycin) per well. For hypoxia
treatment, explants (n 6)were cultured at 37C, 5%CO2 in an
atmosphere of 20 or 1%O2 for 24 h. The JAR (HTB-144) cho-
FIG. 1. Messenger RNA expressions in normal and preeclamptic
placentas (n  16 in each group). LOX-1 (A), CD36 (B), SR-A (C), sFlt-1
(D), Leptin (E) are shown. Values were normalized to those of GAPDH.
Data are presented as the median value with interquartile range.
**, P  0.01; ***, P  0.001.
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riocarcinomacell linewasobtained fromAmericanTypeCulture
Collection (Manassas, VA) and cultured in RPMI 1640medium
supplemented with 10% fetal calf serum, 100 U/ml penicillin,
and 100 g/ml streptomycin at 37 C, 20% O2, 5% CO2.
Diethylmaleate (DEM) treatment
The JAR cells grown in six-well plates and a 10-cm dish for
RNA extraction and protein extraction, respectively, were
treated with or without 100 M DEM (Wako Pure Chemical
Industries, Osaka, Japan), a typical Nrf2 activating electrophilic
agent. After 3, 6, 9, and 24 h, Nrf2 protein and mRNA of HO-1
andLOX-1weremeasured.The experimentswereperformed six
times in duplicates (n  6). Placental explants (n  6) were
cultured at 37 C, 20% O2, 5% CO2 with or without 100 M
DEM. After 6 and 24 h, both protein and mRNA of HO-1 were
measured.
oxLDL treatment
oxLDLandnative LDL (nLDL)were purchased from Intracel
(Frederick, MD). Purified normal human IgG was purchased
from R&D Systems (Minneapolis, MN). TS92, an antihuman
LOX-1 antibody, was a kind gift fromDr. T. Sawamura (Osaka,
Japan). JAR cells grown in 48-well plates or a 6-cm dish were
treatedwith orwithout oxLDL (100g/ml) for 3, 6, 9, and 24 h.
The cells were also tested after being pretreated with TS92 (30
g/ml) or normal human IgG (30 g/ml) and later treated with
oxLDL (100 g/ml) or nLDL (100 g/ml)
for 9 h. After harvesting cells, mRNA and
protein of HO-1 and Nrf2 was measured.
The experiments were performed six times
in triplicates (n  6).
Statistical analysis
The results of normally distributed con-
tinuous variables are expressed as the
mean  SEM (range), whereas those with
skewed distribution were expressed as the
median value with (interquartile range).
Statistical comparisons were performed
with aMann-WhitneyU test and a two-way
ANOVA followed by Bonferroni test, and a
one-way ANOVA followed by a Tukey test
as appropriate, using Prism 4.0 (GraphPad




The features of patients are shown in
Table 1.Gestational age at deliverywas
earlier in the preeclampsia group than
in the normal pregnancy group. Neo-
natal weight was lighter in the pre-
eclampsia group than in the normal
pregnancy group. Among 16 preeclamp-
tic women, seven were early-onset (34
wk gestation) preeclampsia and nine
were late-onset (	34 wk gestation) pre-
eclampsia. All patients are not habitual
smokers and all preeclamptic women
were diagnosed as severe preeclampsia.
Expression of LOX-1 in normal
and preeclamptic placentas
Quantitative real-time PCR analy-
sis showed that mRNA expression of
LOX-1 was significantly decreased in
preeclamptic placentas compared with
FIG. 2. Expression of LOX-1 protein in placenta and mRNA expression under hypoxic
condition in placental explant culture. A, Western blotting for LOX-1 in normal and
preeclamptic placentas (n  5 in each group). An arrow indicates mature form of LOX-1 (52
kDa), and arrowheads show the precursor forms (40 kDa). B, The bands were quantified using
densitometric analysis normalized to -actin. The densitometric analysis was carried out on all
bands. Data are presented as the median value with interquartile range. *, P  0.05. C,
Immunohistochemical staining for LOX-1 in normal term placental villi. D, Negative control.
Bar, 50 m. Arrowheads point at endothelial cells. E, LOX-1 mRNA expression in placental
explants cultured in 20 or 1% O2 (n  6). Values were normalized to those of GAPDH.
**, P  0.01.
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normal placentas (n  16 in each group) (Fig. 1A). The
mRNAexpressions ofCD36 and SR-A, predominant recep-
tors foroxLDL,werealso significantly lower inpreeclamptic
placentas (Fig. 1, B and C). We confirmed the significantly
higher mRNA of sFlt-1 and leptin in preeclamptic placentas
comparedwithnormalcontrolsbecause theyarewellknown
to be up-regulated in preeclamptic placenta (Fig. 1, D and
E). Western blot analysis of placental lysates demon-
strated that protein level of LOX-1 was significantly re-
duced in preeclamptic placentas compared with the nor-
mal controls (n 5 in each group) (Fig. 2, A and B). With
immunohistochemistry, LOX-1 immunostaining was ob-
served in villous trophoblasts in normal term placenta; on
the other hand, this was not detected in vascular endothe-
lial cells (Fig. 2, C and D).
The mRNA expression of LOX-1 in placental
explants under hypoxic condition
We cultured placental explants under normal and hy-
poxic conditions (20 and 1% O2, respectively) (n  6 in
each group). After 24 h cultures, hypoxia resulted in sig-
nificantly decreased LOX-1 mRNA expression (Fig. 2E).
Nrf2 activation and HO-1 mRNA are decreased in
preeclamptic placentas
We analyzed Nrf2 activation by Western blot analysis
using nuclear extracts from normal and preeclamptic pla-
centas (n  5 in each group). Nuclear accumulation of
Nrf2 was significantly decreased in preeclampsia com-
pared with normal controls (Fig. 3, A and B). Next, we
assessed mRNA expression of HO-1, which is a main tar-
get gene of Nrf2, and found significant low expression of
that in preeclamptic placentas by quantitative real-time
PCR (n  16 in each group) (Fig. 3C).
Regulation of HO-1 mRNA by Nrf2 activation
We cultured the JAR choriocarcinoma cell line with or
without DEM (100 M), a typical Nrf2-activating agent.
DEM administration significantly up-regulated HO-1
mRNA at 6 h and then decreased (Fig. 4A). The DEM
treatment also augmented nuclear accumulation of Nrf2
and HO-1 protein expression after 6–9 h (Fig. 4B),
whereas it did not up-regulate LOX-1mRNA (Fig. 4C). In
cultured placental explants, DEM (100 M) significantly
increased HO-1 mRNA at 6 h and then decreased (Fig.
4D). The HO-1 protein expression was also increased by
DEM treatment (Fig. 4E). The experiments were per-
formed six times in duplicates (n  6).
Role of LOX-1 on the regulation of HO-1 by oxLDL
In JAR cells,HO-1mRNAwas up-regulated by oxLDL
(100g/ml) and increased in a time-dependentmanner up
to 9 h and then decreased (Fig. 5A). Both nuclear accu-
mulation of Nrf2 and HO-1 protein expression were in-
creased by oxLDL treatment (Fig. 5B). In the same culture
model, we inhibited the LOX-1 mediated signal by TS92,
an antihumanLOX-1 antibody, and this pretreatment sig-
nificantly alleviated the HO-1 up-regulation induced by
oxLDL for 9h,whereas nLDLdid not affectHO-1mRNA
expression (Fig. 5C). The experiments were performed six
times in duplicates (n  6).
Discussion
In the present study, we first accurately demonstrated that
LOX-1 expression in preeclamptic placentas is decreased
FIG. 3. Nrf2 activation (n  5 in each group) and HO-1 mRNA
expression (n  16 in each group) in normal and preeclamptic (PE)
placentas. A, Western blotting for Nrf2 using nuclear extract from
normal and preeclamptic placentas. The far right lane contains nuclear
extract of Hela cells treated with DEM (100 M) as a positive control
(PC). B, Densitometric analysis of Nrf2 expression normalized to TATA
binding protein (TBP). C, HO-1 mRNA expression in normal and
preeclamptic placentas. Values were normalized to those of GAPDH.
Data are presented as the median value with interquartile range.
* P  0.05, ** P  0.01.
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at both themRNAand the protein level. Although LOX-1
is the most abundant in placenta, there have been few
studies on LOX-1 in placenta. Contrasting to our results,
Lee et al. (23) reported the elevated LOX-1 expression in
the placentas of women with preeclampsia by Western
blotting and immunohistochemistry. It is unclear what
causes this discrepancy. The differences in phenotype of
preeclamptic patients enrolled in these studies may be one
of the reasons. We tried to collect placental tissues from
the homogenous group with regard to mode of delivery,
age, body mass index, and other factors. In addition, to
confirm the quality of the samples, we also evaluated the
sFlt-1 and leptin, in which the up-reg-
ulation in preeclampsia are well estab-
lished (19, 24), and we found both
genes were significantly increased in
our preeclamptic placentas. We there-
fore believed the samples were appro-
priately obtained from preeclamptic
placentas and concluded that LOX-1
expression is significantly decreased in
preeclamptic placentas. Ethier-Chias-
son et al. (25) demonstrated that pla-
cental LOX-1 expression is higher in
women with hyperlipidemia or gesta-
tional diabetes mellitus. Satoh et al.
(26) have shown higher expression of
LOX-1 mRNA in the first-trimester
placenta than in the term placenta and
suggested a connection with increasing
oxidative stress at the end of the first
trimester in placenta. It is reasonable
that hyperlipidemia, gestational diabe-
tes mellitus, or oxidative stress may
cause the increase of LOX-1; however,
our results suggested that LOX-1 is not
increased in preeclamptic placenta despite
oxidative stress, although the mechanism
has not been elucidated.
InWesternblot analysis,wedetected
three bands for LOX-1. Similar results
were reportedpreviously and suggested
that two of the three bands were pre-
cursor forms, and the other onewas the
mature form (27). LOX-1 is synthe-
sized as a precursor formand processed
intomature formby glycosylation (28).
Xie et al. (29) found that the extracel-
lular C-terminal lectin-like domain is
sufficient for the binding to oxLDL,
and this domain is not glycosylated,
which suggests the glycosylation of
LOX-1 is not a prerequisite for the
binding of ligand. Accordingly, we regarded these three
signals as functional LOX-1 and quantified. Immunohis-
tochemistry revealed that LOX-1 immunostaining was
observed in villous trophoblasts but not in vascular endo-
thelial cells. This is similar to the previous report by Satoh
et al. (26), andLOX-1 is expressedmainly in trophoblasts.
We also demonstrated the significantly decreased
LOX-1 mRNA in cultured placental explants under hy-
poxic condition, indicating that hypoxia can down-regu-
late LOX-1 expression in placenta. Although several stim-
uli or pathological conditions have been studied to
FIG. 4. Effect of DEM on JAR cells and placental explant culture. Time course of HO-1 (A)
and LOX-1 (C) mRNA expression in JAR cells treated with DEM (100 M). Values were
normalized to those of GAPDH. B, A representative Western blotting image for the time
courses of Nrf2 nuclear accumulation and HO-1 expression in cytosolic protein in JAR cells
treated with DEM (100 M). D, Time courses of HO-1 mRNA expressions in placental explant
treated with DEM (100 M). Values were normalized to those of GAPDH. E, A representative
Western blotting image for the time course of HO-1 expression in cytosolic protein of
placental explant treated with DEM (100 M). Data are presented as the mean  SEM.
*, P  0.05. The experiments were performed six times in duplicates (n  6).
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enhance LOX-1 gene expression (11, 12), little is known
so far with regards to factors reducing LOX-1 expression.
Here, for the first time, we revealed the pathological con-
dition that down-regulates LOX-1 expression in placenta.
Hypoxia is one of the factors involved in the onset of
preeclampsia. At the early stage of pregnancy, impaired
invasion and adaptation of extravillous trophoblasts to
maternal spiral artery leads to reduced uteroplacental per-
fusion and placental hypoxia (2). It has been implicated in
the pivotal pathogenesis of preeclampsia. So the decrease
in LOX-1 expression may be derived from the early path-
ological alteration in placenta.
LOX-1 expression in placenta is the most abundant
among the organs (9), and it can be the key molecule to
regulate the serum oxLDL level. Ishigaki et al. (30) re-
ported an actual example demonstrating the involvement
of LOX-1 in systemic lipid metabolism
regulation. Hepatic LOX-1 overex-
pression enhanced oxLDL uptake in
apolipoprotein E-deficient mice, and
the plasma oxLDL level was markedly
decreased. In women with preeclamp-
sia, serum lipid levels arehigher (4), and
elevated oxLDL can be a risk factor of
preeclampsia (31), suggesting that ab-
errant lipidmetabolismmayhave a role
in the pathogenesis of preeclampsia. In
addition to LOX-1, CD36 and SR-A
are considered predominant receptors
for oxLDL (22), and mRNA expres-
sions of both were revealed to be lower
in preeclamptic placenta in the present
study. These results suggest that the
scavenger function against oxLDL is
weakened in preeclamptic placentas.
Therefore, it can be speculated that
hypoxia at an early stage lead to de-
creased oxLDL receptors, and conse-
quently, it may cause increasing serum
oxLDL, which can give rise to further
maternal endothelial dysfunction.
Next, we focused on Nrf2, a tran-
scriptional factor that regulates antiox-
idant responsive element mediated in-
duction of cytoprotective genes in
response to oxidative stress (21). Under
basal conditions, Nrf2 is sequestered in
cytoplasm by binding to the Kelch-like
ECH-associated protein 1 and is de-
graded by a proteasome pathway (32).
However, upon exposure to oxidative
or electrophilic stress, Nrf2 is dissoci-
ated from Kelch-like ECH-associated
protein 1, accumulates in the nucleus, and induces the
antioxidant genes.
Nrf2 is widely acknowledged as the predominant up-
stream regulator of HO-1. Despite its importance, there has
been only one study that dealt with Nrf2 activation in pla-
centa so far, providing nuclear accumulation of Nrf2 in cy-
totrophoblasts by immunohistochemistry (33). We showed
here not only significantly lower Nrf2 activation but also
decreased HO-1 mRNA in preeclamptic placentas. To in-
vestigate the role ofNrf2 in placenta,we examined the effect
ofDEM, anNrf2 activator, in the JARcell line andplacental
explant culture.We found that DEM certainly up-regulated
HO-1 expression in both JAR cells and placental explants.
Although it is reported that oxLDL activates Nrf2 in
murine macrophages (22), Nrf2 was less activated in pre-
FIG. 5. Induction of HO-1 by oxLDL and effect of anti-LOX-1 antibody. A, Time courses of
HO-1 mRNA expression in JAR cells treated with oxLDL (100 g/ml). B, A representative
Western blotting image of Nrf2 nuclear accumulation and HO-1 expression in cytosolic
protein in JAR cells treated with oxLDL (100 g/ml). C, HO-1 mRNA expression in JAR cells
treated with oxLDL (100 g/ml) in the presence or absence of TS92 (30 g/ml) or normal
human IgG (30 g/ml) and treated with nLDL (100 g/ml) for 9 h. Values were normalized to
those of GAPDH. Data are presented as the mean  SEM. *, P  0.05. Different letters denote
significant difference (P  0.001). The experiments were performed six times in triplicates
(n  6).
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eclamptic placenta despite a high serum level of oxLDL
and increasing oxidative stress in womenwith preeclamp-
sia. To address this query, we assessed the role of LOX-1
in JAR cells using TS92, a blocking anti-LOX-1 antibody.
We confirmed in advance that only LOX-1, but neither
CD36 nor SR-A, was expressed in JAR and considered
that blockade of LOX-1 was enough to prevent JAR cells
from oxLDL uptake. We revealed that oxLDL activated
Nrf2 and up-regulated HO-1 expression in JAR cells and
that LOX-1blockade resulted in the alleviation of increas-
ing HO-1 mRNA induced by oxLDL. These results sug-
gest that oxLDL might be less internalized due to de-
creased LOX-1 in preeclamptic placenta than in the
healthy state, leading to lower Nrf2 activation. When
Nrf2 is not activated appropriately in trophoblasts, they
fail to increase antioxidative genes, and both the mother
and fetus may be affected against oxidative stress. In this
study, LOX-1 mRNAwas unchanged by the Nrf2 activa-
tor. It is currently unclear how the LOX-1 expression was
decreased in preeclamptic placenta, and that is now under
investigation.
In conclusion, to the best of our knowledge, this is the
first study describing decreased LOX-1 expression and
reduced Nrf2 activation in preeclamptic placenta. In ad-
dition, we have also shown the relevance between LOX-1
and Nrf2 through the assessment of HO-1 expression in-
duced by oxLDL. The decrease in LOX-1 expression may
contribute not only to maternal high serum oxLDL in
woman with preeclampsia, although this needs further
investigation, but also to lower Nrf2 activation in pla-
centa. Our findings provided novel insights into the cru-
cial role of LOX-1 and Nrf2 in placenta and paved the
way for the precise comprehension of the pathogenesis
of preeclampsia.
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